#8560. Endometrial regenerative cells with galectin-9 high-expression attenuate experimental autoimmune hepatitis

October 2026publication date
Proposal available till 30-05-2025
4 total number of authors per manuscript4500 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Biochemistry, Genetics and Molecular Biology (miscellaneous);
Medicine (miscellaneous);
Molecular Medicine;
Cell Biology;
Places in the authors’ list:
place 1place 2place 3place 4
FreeFreeFreeFree
1350 $1200 $1050 $900 $
Contract №8560.1 Contract №8560.2 Contract №8560.3 Contract №8560.4
1 place - free (for sale)
2 place - free (for sale)
3 place - free (for sale)
4 place - free (for sale)

Abstract:
This study aims to explore the role of Galectin-9 (Gal-9) in the clinical treatment of autoimmune hepatitis with endometrial regenerative cells (ERCs). Gal-9 appears as an essential modulator, which was required by ERCs in regulating T cell response and attenuating ConA-induced experimental hepatitis.
Keywords:
Autoimmune hepatitis; Concanavalin A-induced hepatitis; Endometrial regenerative cell; Galectin-9

Contacts :
0